Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging securities fraud and unlawful business practices related to the company's New Drug Application for aficamten [1]. Summary by Relevant Sections Class Action Details - Investors are encouraged to contact Pomerantz LLP to join the class action, with a deadline to appoint a Lead Plaintiff by November 17, 2025 [1]. - The lawsuit centers on whether Cytokinetics and its officers engaged in fraudulent activities concerning their securities [1]. FDA Interaction and Stock Impact - On March 10, 2025, Cytokinetics announced that the FDA would not hold an advisory committee meeting for aficamten's NDA [1]. - The FDA extended the action date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the need for a Risk Evaluation and Mitigation Strategy (REMS) that was not included in the original NDA [1]. - Following this announcement, Cytokinetics' stock price dropped by $5.57, or 12.98%, closing at $37.35 on May 2, 2025 [1]. - On May 6, 2025, CEO Robert I. Blum revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, leading to a further stock price decline of $2.70, or 7.36%, closing at $33.97 [1].

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly making false and misleading statements regarding the New Drug Application (NDA) for aficamten, which may have caused investor losses during the specified Class Period from December 27, 2023, to May 6, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, indicating it would occur in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [5]. - Investors who purchased Cytokinetics common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, which has a strong track record in securities class actions, is representing the investors and encourages them to select qualified counsel with proven success [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 17, 2025, to represent the interests of the class members in the litigation [1][3].

Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and prospects, which led to investor losses [1]. Group 1: Cytokinetics, Incorporated (NASDAQ: CYTK) - The class period for Cytokinetics is from December 27, 2023, to May 6, 2025, with a lead plaintiff deadline of November 17, 2025 [2]. - Allegations include the failure to disclose the omission of a Risk Evaluation and Mitigation Strategy (REMS) from the initial New Drug Application (NDA), which resulted in a three-month delay in FDA approval processes [2]. - Defendants' positive statements about the company's business were deemed materially misleading due to these omissions [2]. Group 2: Quanex Building Products Corporation (NYSE: NX) - The class period for Quanex is from December 12, 2024, to September 5, 2025, with a lead plaintiff deadline of November 18, 2025 [4]. - The complaint alleges that the company underinvested in tooling and equipment maintenance, leading to degraded conditions that could incur significant costs and delay expected benefits from integration efforts [4]. - Positive statements made by the defendants regarding the company's operations were found to lack a reasonable basis due to these undisclosed issues [4]. Group 3: Jasper Therapeutics, Inc. (NASDAQ: JSPR) - The class period for Jasper is from November 30, 2023, to July 3, 2025, with a lead plaintiff deadline of November 18, 2025 [6]. - Allegations include the lack of necessary controls to ensure third-party manufacturers complied with current Good Manufacturing Practices (cGMP), which could negatively impact clinical trial results and the company's product prospects [6]. - Defendants' positive statements about the company's business and financial prospects were considered materially misleading due to these failures [6]. Group 4: KBR, Inc. (NYSE: KBR) - The class period for KBR is from May 6, 2025, to June 19, 2025, with a lead plaintiff deadline of November 18, 2025 [8]. - The complaint alleges that the company misled investors about the partnership with TRANSCOM, despite knowing of material concerns regarding HomeSafe's ability to fulfill contract obligations [8]. - Positive statements made by the defendants regarding the company's operations were found to lack a reasonable basis due to these undisclosed concerns [8].

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, potentially causing financial damages to investors [1][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Cytokinetics common stock between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made false statements about the expected FDA approval for aficamten, claiming it would occur in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [4]. Group 2: Investor Information - Investors who purchased Cytokinetics stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][5]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].

Accessibility StatementSkip Navigation LOS ANGELES, Sept. 25, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics " or "the Company") (NASDAQ: CYTK ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokine ...

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for allegedly making false and misleading statements regarding the New Drug Application (NDA) for aficamten, which could impact the company's regulatory approval timeline [1][8]. Allegations - Defendants are accused of making materially false statements about the expected timeline for the NDA submission and approval process for aficamten, claiming FDA approval was anticipated in the second half of 2025 with a PDUFA date of September 26, 2025 [8]. - The company allegedly failed to disclose significant risks, particularly the omission of a required Risk Evaluation and Mitigation Strategy (REMS), which could lead to delays in regulatory approval [8]. Key Dates - Investors must contact the law firm before November 17, 2025, to be eligible for the lead plaintiff motion deadline [4]. Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, with over 125 years of experience in securities litigation, is representing the investors in this case, emphasizing their commitment to justice for those financially harmed by misrepresented statements [5].

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CYTOKINETICS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIAL ...

NEW ORLEANS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) - ...